Hong‐Jie Jhou, Cho-Hao Lee, Yu‐Chi Tsai, Po‐Huang Chen, Li‐Yu Yang
{"title":"血栓切除术值得用于孤立性大脑后动脉闭塞吗?元分析和试验序列分析","authors":"Hong‐Jie Jhou, Cho-Hao Lee, Yu‐Chi Tsai, Po‐Huang Chen, Li‐Yu Yang","doi":"10.1161/svin.123.001084","DOIUrl":null,"url":null,"abstract":"\n \n Thrombectomy is well‐established management for acute ischemic stroke involving large vessel occlusion. However. the potential efficacy of thrombectomy for isolated posterior cerebral artery occlusion remains limited. The study aims to evaluate the benefits of thrombectomy for isolated posterior cerebral artery occlusion.\n \n \n \n We searched PubMed, Cochrane, and Embase for articles published until September 2023. The primary outcome was good functional outcome at 3 months. The secondary outcomes included excellent functional outcome at 3 months and early neurological improvement. The safety outcomes were symptomatic intracerebral hemorrhage, and mortality at 3 months.\n \n \n \n Seven retrospective studies involving 2560 patients with isolated posterior cerebral artery occlusion were included (876 patients receiving thrombectomy). The odds ratio (OR) of good functional outcome at 3 months was 0.93 (95% CI, 0.68–1.28) between 2 groups. The OR of excellent functional outcome (OR 1.23; 95% CI 0.92–1.64) and early neurological improvement (OR 1.82; 95% CI 0.97–3.40) were not different between the 2 groups. Compared with patients with best medical management, those with thrombectomy demonstrated a significantly increased risk of mortality (OR 1.81; 95% CI 1.24–2.65), whereas the risk of symptomatic intracerebral hemorrhage (OR 2.033; 95% CI 0.996–4.148) did not show an increase. Additionally, the results of trial sequential analysis indicated all outcomes were inconclusive.\n \n \n \n Thrombectomy stands as an available procedure for patients with isolated posterior cerebral artery occlusion; however, it shows no notable benefits in reducing symptomatic intracerebral hemorrhage risk or enhancing function and may raise mortality compared with standard medical management. Further randomized controlled trials are necessary to yield more conclusive evidence.\n","PeriodicalId":21977,"journal":{"name":"Stroke: Vascular and Interventional Neurology","volume":"121 8","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Is Thrombectomy Worth It for Isolated Posterior Cerebral Artery Occlusion? Meta‐Analysis and Trial Sequential Analysis\",\"authors\":\"Hong‐Jie Jhou, Cho-Hao Lee, Yu‐Chi Tsai, Po‐Huang Chen, Li‐Yu Yang\",\"doi\":\"10.1161/svin.123.001084\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n \\n Thrombectomy is well‐established management for acute ischemic stroke involving large vessel occlusion. However. the potential efficacy of thrombectomy for isolated posterior cerebral artery occlusion remains limited. The study aims to evaluate the benefits of thrombectomy for isolated posterior cerebral artery occlusion.\\n \\n \\n \\n We searched PubMed, Cochrane, and Embase for articles published until September 2023. The primary outcome was good functional outcome at 3 months. The secondary outcomes included excellent functional outcome at 3 months and early neurological improvement. The safety outcomes were symptomatic intracerebral hemorrhage, and mortality at 3 months.\\n \\n \\n \\n Seven retrospective studies involving 2560 patients with isolated posterior cerebral artery occlusion were included (876 patients receiving thrombectomy). The odds ratio (OR) of good functional outcome at 3 months was 0.93 (95% CI, 0.68–1.28) between 2 groups. The OR of excellent functional outcome (OR 1.23; 95% CI 0.92–1.64) and early neurological improvement (OR 1.82; 95% CI 0.97–3.40) were not different between the 2 groups. Compared with patients with best medical management, those with thrombectomy demonstrated a significantly increased risk of mortality (OR 1.81; 95% CI 1.24–2.65), whereas the risk of symptomatic intracerebral hemorrhage (OR 2.033; 95% CI 0.996–4.148) did not show an increase. Additionally, the results of trial sequential analysis indicated all outcomes were inconclusive.\\n \\n \\n \\n Thrombectomy stands as an available procedure for patients with isolated posterior cerebral artery occlusion; however, it shows no notable benefits in reducing symptomatic intracerebral hemorrhage risk or enhancing function and may raise mortality compared with standard medical management. Further randomized controlled trials are necessary to yield more conclusive evidence.\\n\",\"PeriodicalId\":21977,\"journal\":{\"name\":\"Stroke: Vascular and Interventional Neurology\",\"volume\":\"121 8\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Stroke: Vascular and Interventional Neurology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1161/svin.123.001084\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stroke: Vascular and Interventional Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1161/svin.123.001084","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
血栓切除术是治疗涉及大血管闭塞的急性缺血性脑卒中的行之有效的方法。然而,血栓切除术对孤立性大脑后动脉闭塞的潜在疗效仍然有限。本研究旨在评估血栓切除术对孤立性大脑后动脉闭塞的益处。 我们检索了PubMed、Cochrane和Embase上截至2023年9月发表的文章。主要结果是 3 个月时的良好功能预后。次要结果包括 3 个月时的良好功能预后和早期神经功能改善。安全性结果为症状性脑出血和 3 个月时的死亡率。 七项回顾性研究共纳入了2560名孤立性大脑后动脉闭塞患者(876名患者接受了血栓切除术)。两组患者 3 个月后功能预后良好的几率比(OR)为 0.93(95% CI,0.68-1.28)。两组患者的优良功能预后(OR 1.23;95% CI 0.92-1.64)和早期神经功能改善(OR 1.82;95% CI 0.97-3.40)的比值比没有差异。与接受最佳内科治疗的患者相比,接受血栓切除术的患者的死亡风险显著增加(OR 1.81;95% CI 1.24-2.65),而症状性脑出血的风险(OR 2.033;95% CI 0.996-4.148)没有增加。此外,试验序列分析的结果表明,所有结果均无定论。 血栓切除术是一种适用于孤立性大脑后动脉闭塞患者的手术,但与标准的药物治疗相比,它在降低症状性脑出血风险或增强功能方面没有明显的益处,而且可能会提高死亡率。有必要进一步开展随机对照试验,以获得更多确凿证据。
Is Thrombectomy Worth It for Isolated Posterior Cerebral Artery Occlusion? Meta‐Analysis and Trial Sequential Analysis
Thrombectomy is well‐established management for acute ischemic stroke involving large vessel occlusion. However. the potential efficacy of thrombectomy for isolated posterior cerebral artery occlusion remains limited. The study aims to evaluate the benefits of thrombectomy for isolated posterior cerebral artery occlusion.
We searched PubMed, Cochrane, and Embase for articles published until September 2023. The primary outcome was good functional outcome at 3 months. The secondary outcomes included excellent functional outcome at 3 months and early neurological improvement. The safety outcomes were symptomatic intracerebral hemorrhage, and mortality at 3 months.
Seven retrospective studies involving 2560 patients with isolated posterior cerebral artery occlusion were included (876 patients receiving thrombectomy). The odds ratio (OR) of good functional outcome at 3 months was 0.93 (95% CI, 0.68–1.28) between 2 groups. The OR of excellent functional outcome (OR 1.23; 95% CI 0.92–1.64) and early neurological improvement (OR 1.82; 95% CI 0.97–3.40) were not different between the 2 groups. Compared with patients with best medical management, those with thrombectomy demonstrated a significantly increased risk of mortality (OR 1.81; 95% CI 1.24–2.65), whereas the risk of symptomatic intracerebral hemorrhage (OR 2.033; 95% CI 0.996–4.148) did not show an increase. Additionally, the results of trial sequential analysis indicated all outcomes were inconclusive.
Thrombectomy stands as an available procedure for patients with isolated posterior cerebral artery occlusion; however, it shows no notable benefits in reducing symptomatic intracerebral hemorrhage risk or enhancing function and may raise mortality compared with standard medical management. Further randomized controlled trials are necessary to yield more conclusive evidence.